Table 4 Relationship between MPC2 expression and clinicopathological features of prostate cancer
From: MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
Clinicopathologic | n | MPC2 expression | |||
|---|---|---|---|---|---|
Variable | Â | Positive | Weak positive | Negative | P value1 |
| Â | 88 | 23(26.14%) | 49(55.68%) | 16(18.18) | Â |
Age(yr) | Â | Â | Â | Â | 0.652 |
≤71 | 45 | 10(22.22%) | 27(60.00%) | 8(17.78%) |  |
>71 | 43 | 13(30.23%) | 22(51.16%) | 8(18.60%) | Â |
Gleason score | Â | Â | Â | Â | 0.367 |
<7 | 27 | 9(33.33%) | 12(44.44%) | 6(22.22%) | Â |
7–10 | 61 | 14(22.95%) | 37(60.66%) | 10(16.39%) |  |
PSA (ng/ml) | Â | Â | Â | Â | 0.763a |
≤10 | 10 | 4(40.00%) | 5(50.00%) | 1(10.00%) |  |
> 10 and ≤ 20 | 10 | 1(10.00%) | 5(50.00%) | 4(40.00%) |  |
> 20 | 68 | 18(26.48%) | 39(57.35%) | 11(16.18%) | Â |
UICC stage | Â | Â | Â | Â | 0.000 |
pT2 | 67 | 13(19.40%) | 47(70.15%) | 7(10.45%) | Â |
pT3-pT4 | 21 | 10(47.62%) | 2(9.52%) | 9(42.86%) | Â |
lymph node metastasis | Â | Â | Â | Â | 0.002 |
Negative | 74 | 22(29.73%) | 43(58.11%) | 9(12.16%) | Â |
Positive | 14 | 1(7.14%) | 6(42.86%) | 7(50.00%) | Â |
distant metastasis | Â | Â | Â | Â | 0.939 |
Negative | 63 | 17(26.98%) | 35(55.56%) | 11(17.46%) | Â |
Positive | 25 | 6(24.00%) | 14(56.00%) | 5(20.00%) | Â |